.png){kind=icon}
.png){kind=icon}
Return
Clinical usefulness of fecal calprotectin in assessing disease activity and endoscopic remission in intestinal Behçet's disease
.png){kind=icon}
PRE
AI
W
S
H
S
J
T
J
DOI：10.5217/ir.2025.00267.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Background/Aims: Intestinal Beh & ccedil;et's disease (BD) is a manifestation of BD involving the gastrointestinal tract. Although fecal calprotectin (FC) is a useful inflammatory marker, its role in intestinal BD is unclear. Methods: We retrospectively analyzed 78 patients with intestinal BD to evaluate correlations between FC levels and the Disease Activity Index for Intestinal Beh & ccedil;et's Disease (DAIBD), C-reactive protein (CRP), and erythrocyte sedimentation rate. FC and CRP levels were compared between patients in endoscopic remission and those with active disease. Receiver operating characteristic (ROC) curve analysis was used to evaluate FC's ability to predict endoscopic activity and ulcer size. Results: FC levels significantly correlated with DAIBD scores (r= 0.253, P= 0.025) and CRP (r= 0.227, P= 0.046). Patients with endoscopically active disease had higher FC (1,124 +/- 1,957 mu g/g vs. 367 +/- 1,208 mu g/g; P< 0.001) and CRP levels (16.0 +/- 23.7 mg/L vs. 14.4 +/- 46.5 mg/L; P= 0.027) than those in remission. Patients with larger ulcers ( >= 30 mm) had higher FC levels than those with smaller ulcers (2,212 +/- 2,609 mu g/g vs. 962 +/- 1,822 mu g/g; P= 0.034). An FC cutoff level of 176 mu g/g discriminated active endoscopic disease (sensitivity 59.3%, specificity 83.3%), with an area under the ROC curve (AUC) of 0.724 (95% confidence interval, 0.605-0.843; P= 0.002), outperforming CRP (AUC, 0.657). Conclusions: FC levels correlated with DAIBD scores and endoscopic inflammation in intestinal BD. FC outperformed CRP in detecting endoscopic activity, supporting its use in disease management.
Keywords:
Behcet syndrome
Gastrointestinal diseases
Leukocyte L1 antigen complex
Inflammation
Biomarkers
Journal
IF:
3.9
Papers:
371
Citations:
1.6K
Organization
Cited Papers